Durvalumab (D) +/- tremelimumab (T) plus platinum-etoposide (EP) in 1L extensive-stage (ES) SCLC: Characteristics of long-term survivors in the CASPIAN study
Yazar
Hochmair, M. J.
Reinmuth, N.
Goldman, J. W.
Garassino, M. C.
Chen, Y.
Hotta, K.
Poltoratskiy, A.
Trukhin, D.
Ji, J. H.
ÖZGÜROĞLU, MUSTAFA
Statsenko, G.
Voitko, O.
Conev, N. V.
Bondarenko, I.
Mann, H.
Xie, M.
Shrestha, Y.
Chugh, P.
Dalvi, T.
Paz-Ares, L.